HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, announced it will hold a conference call on Thursday, Nov. 13, 2025, at 4:30 p.m. ET to discuss its third quarter results for the period ended Sept. 30, 2025. The company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones. A detailed press release will be issued prior to the call.
This announcement is significant because it comes on the heels of HeartBeam receiving FDA clearance in December 2024 for its 3D ECG technology for arrhythmia assessment. The company is now awaiting FDA review of its 12-Lead ECG synthesis software, which could expand its platform's capabilities. The conference call offers investors and stakeholders insight into the company's progress toward commercialization of the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG.
HeartBeam's platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. This approach aims to enable physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining cardiac health management. The company holds over 20 issued patents related to technology enablement, underscoring its intellectual property position.
The third quarter results and conference call come at a critical juncture as HeartBeam advances its regulatory and commercial strategies. The company's ability to secure additional FDA clearances and launch its products will be key to its growth. Investors and industry observers will be watching for updates on the 12-lead software review timeline and commercial-readiness activities. For more details, the full press release is available at https://ibn.fm/5mXsb.
HeartBeam's progress highlights the growing trend toward remote cardiac monitoring and personalized medicine. With its 3D ECG technology already cleared for arrhythmia assessment, the company is positioned to address the need for accessible, portable cardiac diagnostics. The upcoming conference call will provide a forum for management to discuss these developments and answer questions from analysts and investors. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
As with any forward-looking statements, there are risks and uncertainties that could affect actual results, including those set forth in the company's SEC filings. The conference call on November 13 will be an opportunity to assess HeartBeam's trajectory in transforming cardiac care through its innovative technology platform.
